Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | CLPP | Q16740 | 1/20 | 0.30 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14034677 | 0.91 | DOCK5 (0.30) | DOCK5 | |
| SCHEMBL12129232 | 0.90 | GRM2 (0.33) | HTR2AGRM2DRD4AKR1B1TNIK | |
| SCHEMBL3490121 | 0.90 | GRM2 (0.33) | HTR2AGRM2DRD4AKR1B1TNIK | |
| SCHEMBL1337247 | 0.90 | GRM2 (0.33) | HTR2AGRM2DRD4AKR1B1TNIK | |
| SCHEMBL1336152 | 0.87 | OPRK1 (0.36) | HTR2AGRM2DRD4AKR1B1P2RX7 | |
| SCHEMBL3615763 | 0.85 | P2RX3 (0.32) | HTR2AGRM2DRD4P2RX7EZH2 | |
| SCHEMBL14007690 | 0.85 | P2RX3 (0.32) | HTR2AGRM2DRD4P2RX7EZH2 | |
| SCHEMBL1337786 | 0.83 | MAOB (0.36) | AKR1B1P2RX7WDR5EZH2 | |
| SCHEMBL1338248 | 0.82 | SIGMAR1 (0.33) | HTR2AGRM2DRD4P2RX7 | |
| SCHEMBL2028051 | 0.82 | WDR5 (0.35) | HTR2AGRM2DRD4AKR1B1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | TYMP, SAMHD1, ACIN1 | HTR2A 2891/4885GRM2 4812/4885DRD4 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.